Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Evogliptin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 known ✓ | P27487 | 19/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | DPP8 | Q6V1X1 | 6/20 | 0.68 |
| ▸ | DPP7 | Q9UHL4 | 6/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Evogliptin SCHEMBL30866226 | 1.00 | DPP4 (1.00) | DPP4KCNH2DPP8DPP7 | |
| Evogliptin SCHEMBL18331680 | 1.00 | DPP4 (1.00) | DPP4KCNH2DPP8DPP7 | |
| Evogliptin SCHEMBL343847 | 1.00 | DPP4 (1.00) | DPP4KCNH2DPP8DPP7 | |
| Evogliptin SCHEMBL2298513 | 1.00 | DPP4 (1.00) | DPP4KCNH2DPP8DPP7 | |
| Evogliptin SCHEMBL2496606 | 0.99 | DPP4 (0.98) | DPP4KCNH2DPP8DPP7 | |
| Evogliptin SCHEMBL2491978 | 0.99 | DPP4 (0.98) | DPP4KCNH2DPP8DPP7 | |
| Evogliptin SCHEMBL2491981 | 0.99 | DPP4 (0.98) | DPP4KCNH2DPP8DPP7 | |
| Evogliptin SCHEMBL2493817 | 0.98 | DPP4 (0.96) | DPP4KCNH2DPP8DPP7 | |
| Evogliptin SCHEMBL2493812 | 0.98 | DPP4 (0.96) | DPP4KCNH2DPP8DPP7 | |
| Evogliptin SCHEMBL2493525 | 0.96 | DPP4 (0.93) | DPP4KCNH2DPP8DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 867 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12636284-B2 | Compositions for use in the prevention and/or treatment of intellectual disability and neurodegenerative diseases in a subject with down syndrome | Universita' Degli Studi Di Roma “La Sapienza” (IT) | 2026-05-26 | — | — | US | claimed |
| EP-4734978-A2 | COMBINATION THERAPIES USING PSILOCYBIN | University of Padova (IT) | 2026-05-06 | — | — | EP | claimed |
| EP-4735023-A2 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE | Piton Therapeutics, Inc. (US) | 2026-05-06 | — | — | EP | claimed |
| US-12599564-B2 | Antidiabetic pharmaceutical compositions | Elite Pharmaceutical Solution Inc. (US) | 2026-04-14 | — | — | US | claimed |
| EP-4694979-A2 | COMPOUNDS FOR UPREGULATING UTROPHIN LEVELS IN MUSCLE CELLS AND METHOD OF APPLICATION THEREOF | Peptris Technologies Private Limited (IN) | 2026-02-18 | — | — | EP | claimed |
| EP-4686474-A1 | DPP-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF AUTOIMMUNE LIVER DISEASES | Delta 4 GmbH (AT) | 2026-02-04 | — | — | EP | claimed |
| EP-4596044-A2 | COMBINATION THERAPY OF GPR119 AGONISTS AND DPP-4 INHIBITORS | Mankind Pharma Ltd. (IN) | 2025-08-06 | — | — | EP | claimed |
| WO-2025104674-A1 | COMBINATION THERAPY FOR TREATING NEURODEGENERATIVE DISORDERS | ARIBIO CO., LTD. (KR) | 2025-05-22 | — | — | WO | claimed |
| EP-4554574-A2 | SMALL MOLECULE REGULATORS OF ALVEOLAR TYPE 2 CELL PROLIFERATION FOR THE TREATMENT OF PULMONARY DISEASES | The Scripps Research Institute (US) | 2025-05-21 | — | — | EP | claimed |
| WO-2025100968-A1 | USE OF COMPOSITION FOR PREVENTING, ALLEVIATING OR TREATING DIABETIC KIDNEY DISEASE COMPRISING ZINC SALT AND CYCLO-HISPRO AS ACTIVE INGREDIENTS | 주식회사 노브메타파마 | 2025-05-15 | — | — | WO | claimed |
| EP-3967302-A1 | COMPOSITION FOR PREVENTING OR TREATING LIVER DISEASES | Acebiomed, Inc. (KR) | 2022-03-16 | — | — | EP | claimed |
| EP-3946343-A1 | LOW-DOSE TRIPLE COMBINATION FORMULATION | The George Institute For Global Health (AU) | 2022-02-09 | — | — | EP | claimed |
| CN-105555275-B | Composition for preventing and treating kidney diseases containing DPP-IV inhibitor | 东亚ST株式会社 | 2021-04-20 | — | — | CN | claimed |
| EP-2351567-B1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF DIABETES OR OBESITY COMPRISING A COMPOUND THAT INHIBITS ACTIVITY OF DIPEPTIDYL PEPTIDASE-IV, AND OTHER ANTIDIABETIC OR ANTIOBESITY AGENTS AS ACTIVE INGREDIENTS | DONG A ST CO LTD (KR) | 2017-11-22 | — | — | EP | claimed |
| EP-2142519-B1 | DPP-IV INHIBITOR INCLUDING BETA-AMINO GROUP, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME FOR PREVENTING AND TREATING A DIABETES OR AN OBESITY | DONG A PHARM CO LTD (KR) | 2014-09-24 | — | — | EP | claimed |
| US-8440669-B2 | Pharmaceutical composition for prevention and treatment of diabetes or obesity comprising a compound that inhibits activity of dipeptidyl peptidase-IV, and other antidiabetic or antiobesity agents as active ingredients | DONG-A PHARMACEUTICAL CO. LTD. (KR) | 2013-05-14 | — | — | US | claimed |
| US-8030315-B2 | DPP-IV inhibitor including beta-amino group, preparation method thereof and pharmaceutical composition containing the same for preventing and treating diabetes or obesity | DONG-A PHARM. CO., LTD. (KR) | 2011-10-04 | — | — | US | claimed |
| US-20110201624-A1 | Pharmaceutical Composition for Prevention and Treatment of Diabetes or Obesity Comprising a Compound that Inhibits Activity of Dipeptidyl Peptidase-IV, and other Antidiabetic or Antiobesity Agents as Active Ingredients | DONG-A PHARMACEUTICAL. CO., LTD (KR) | 2011-08-18 | — | — | US | claimed |
| EP-2351567-A2 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF DIABETES OR OBESITY COMPRISING A COMPOUND THAT INHIBITS ACTIVITY OF DIPEPTIDYL PEPTIDASE-IV, AND OTHER ANTIDIABETIC OR ANTIOBESITY AGENTS AS ACTIVE INGREDIENTS | Dong-A Pharmaceutical Co., Ltd. (KR) | 2011-08-03 | — | — | EP | claimed |
| US-20100120790-A1 | DPP-IV INHIBITOR INCLUDING BETA-AMINO GROUP, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME FOR PREVENTING AND TREATING DIABETES OR OBESITY | DONG-A PHARM. CO., LTD (KR) | 2010-05-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120790-A1 | DPP-IV INHIBITOR INCLUDING BETA-AMINO GROUP, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME FOR PREVENTING AND TREATING DIABETES OR OBESITY | DPP4, DPP7, DPP3 | DPP4 1/4885KCNH2 1962/4885DPP8 5/4885 |
| US-12636284-B2 | Compositions for use in the prevention and/or treatment of intellectual disability and neurodegenerative diseases in a subject with down syndrome | DPP4, DPP3, DPP7 | DPP4 1/4885KCNH2 3480/4885DPP8 5/4885 |
| US-12599564-B2 | Antidiabetic pharmaceutical compositions | GLP1R, DPP4, SLC5A2 | DPP4 2/4885KCNH2 1478/4885DPP8 11/4885 |
| US-20110201624-A1 | Pharmaceutical Composition for Prevention and Treatment of Diabetes or Obesity Comprising a Compound that Inhibits Activity of Dipeptidyl Peptidase-IV, and other Antidiabetic or Antiobesity Agents as Active Ingredients | DPP4, DPP3, DPP7 | DPP4 1/4885KCNH2 3038/4885DPP8 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.